# Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

> **NCT02113800** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 40 (actual)

## Conditions studied

- Poorly Differentiated Malignant Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma, Grade 3
- Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3
- Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
- Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)

## Interventions

- **DRUG:** Everolimus (Afinitor®)

## Key facts

- **NCT ID:** NCT02113800
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113800, "Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02113800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*